These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 8857873

  • 1. Cost-effectiveness of clozapine monitoring after the first 6 months.
    Zhang M, Owen RR, Pope SK, Smith GR.
    Arch Gen Psychiatry; 1996 Oct; 53(10):954-8. PubMed ID: 8857873
    [Abstract] [Full Text] [Related]

  • 2. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.
    Honigfeld G.
    Psychiatr Serv; 1996 Jan; 47(1):52-6. PubMed ID: 8925346
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clozapine-associated agranulocytosis: risk and aetiology.
    Krupp P, Barnes P.
    Br J Psychiatry Suppl; 1992 May; (17):38-40. PubMed ID: 1418887
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand.
    Tunsirimas N, Pariwatcharakul P, Choovanichvong S, Ratta-Apha W.
    Asian J Psychiatr; 2019 Mar; 41():13-16. PubMed ID: 30856469
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A follow-up study of a population of schizophrenic patients treated with clozapine.
    Bourin M, Guitton B, Dailly E, Hery P, Jolliet P.
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Nov; 25(8):1481-95. PubMed ID: 11642649
    [Abstract] [Full Text] [Related]

  • 17. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J.
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [Abstract] [Full Text] [Related]

  • 18. [Hematologic effects of clozapine: evaluation of the international experience].
    Lamarque V.
    Encephale; 1995 Jun; 21 Spec No 3():59-60. PubMed ID: 7628344
    [Abstract] [Full Text] [Related]

  • 19. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.
    Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D.
    Br J Psychiatry; 1996 Oct; 169(4):483-8. PubMed ID: 8894200
    [Abstract] [Full Text] [Related]

  • 20. Clozapine treatment after agranulocytosis induced by classic neuroleptics.
    Bauer M, Mackert A.
    J Clin Psychopharmacol; 1994 Feb; 14(1):71-3. PubMed ID: 7908676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.